Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Transmedics Group Inc chart...

About the Company

transmedics inc. is the world’s leader in portable ex-vivo perfusion and assessment of donor organs for transplantation. the company was founded to address the need for more and better organs for transplantation, and is focused on transforming the standard of care – increasing organ utilization, improving patient outcomes, and reducing transplant costs throughout the heath care system. the ocs™ lung and ocs™ heart systems are ce-marked and in commercial use outside the us, and are currently being reviewed by the fda for u.s. market access. the ocs™ liver is in an fda pivotal trial (the ocs™ liver protect trial) in the united states and a ce-mark trial in (the revive trial) in europe.

CEO

Waleed H. Hassanein

Exchange

NASDAQ

Website

transmedics.com

$241M

Total Revenue

167

Employees

$2B

Market Capitalization

-69.62

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $TMDX News

TransMedics draws bullish view at Piper Sandler on valuation

on MSN ago, source:

TransMedics Group (TMDX) stock gains as Piper Sandler initiated coverage with an Overweight rating and $95 price target, citing attractive valuation. Read more here.

TransMedics Group, Inc. (NASDAQ:TMDX) Q4 2023 Earnings Call Transcript

29d ago, source: InvestingChannel on MSN

TransMedics Group, Inc. (NASDAQ:TMDX) Q4 2023 Earnings Call Transcript February 26, 2024 TransMedics Group, Inc. beats ...

TransMedics Group: Operational Efficiency and Market Positioning Propel Buy Rating

4d ago, source:

Josh Jennings, an analyst from TD Cowen, reiterated the Buy rating on TransMedics Group (TMDX – Research Report). The associated price ...

TransMedics Group: Huge Opportunity In Organ Transplants

16d ago, source: Seeking Alpha

The market is yet to price the huge upside ahead for the company. TransMedics Group, Inc. (NASDAQ:TMDX), a company you probably never heard of, is transforming the organ transplant landscape.

Transmedics Group

7d ago, source: Forbes

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the ...

TransMedics Group Inc TMDX

7d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

TransMedics Group Inc.

29d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

TransMedics Group Inc (TMDX)

22d ago, source: Investing

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...